NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000 Index tracks the performance of the la ...